| OSRX® Prepared Atropine (U.S.N.L.M.) | |||
|---|---|---|---|
| (Myopia prevention) | 1 or 2 drops 0.05%1 to .1% qhs (0.5% starting dose used weekly may be appropriate for high rates of progression.2) |
||
| Chem Specs | atropine sulfate 0.01%, 0.025%, 0.05% | ||
| Quantities | 3.5ml | ||
| Cost | 45.00 OSRX® | ||
| Class | anticholinergic | ||
| Action | Competitive antagonist for the muscarinic acetylcholine receptor. | ||
| Myopia Prevention | Atropine therapy is dose dependent so the magnitude and rate of change of myopia should determine the dosage. The 0.01% concentration is no better than placebo in one study,11. Rebound after cessation can be avoided with a taper regardless of dosage used4. Mydriasis (but not cycloplegia10) is present with low dosages (to 0.05%) and may be addressed with photochromic lenses. |
||
| Increased susceptibility in infants, young children, and in children with blond hair, blue eyes, Down's syndrome, spastic paralysis, or brain damage. |
|||
| Contraindications | Predisposition toward narrow angle glaucoma. Pediatric patients who have previously had a severe systemic reaction to atropine. Hypersensitivity to atropine or product contents. |
||
| Pediatric use | > 3 months | ||
| Pregnancy | Category C | ||
| 0.01% BAK | |||
| Systemic anticholinergics may be associated with increased risk of dementia.6 | |||
2. Polling JR, Tan E, Driessen S, et al. Eye (Lond). 2020 Sep 21.
3. JAMA Ophthalmol; 2021 Jan 14; EPub Ahead of Print; J Wang, Y Li, DC Musch, et. al.
4. Zhu et. al., Efficacy and Safety of 1% Atropine... Int J Med Sci. 2020; 17(2): 176–181.
5. Joachimsen L, Böhringer D, Gross NJ, et al. Ophthalmol Ther. 2019 Jun 12.
6. Risacher, McDonald, Tallman, et al. JAMA April 18, 2016.
7. Zhu Q, Tang Y, Guo L, et al. Int J Med Sci. 2020 Jan;17:176-181.
8. Cooper et. al., Optometry and Vision Science: December 2013 - Volume 90 - Issue 12 - p 1467-1472.
9. Jason C. Yam, et.al.,https://jamanetwork.com/journals/jama/article-abstract/2801319, February, 2023
10. Breliant, et al., Optom Vis Sci. 2023 Jun 6. doi: 10.1097/OPX.02031. Online ahead of print.
11. Repka, Weise, Chandler; et al JAMA Ophthalmol. Published online July 13, 2023. doi:10.1001/jamaophthalmol.2023.2855
12. Zadnick et. al.,JAMA Ophthalmol. 2023 Oct; 141(10): 990–999. Published online 2023 Jun 1. doi: 10.1001/jamaophthalmol.2023.2097